CVS Health stock plunged more than 10% in extended trading on Monday following the Centers for Medicare & Medicaid Services’ proposal to raise Medicare Advantage payment rates by just 0.09% for plan year 2027. The CMS announcement, which fell well below Wall Street’s consensus forecast of a 4%–6% increase, threatens to cut into CVS’s profitability in its growing Aetna Medicare Advantage business. With over 12 million Medicare Advantage members nationwide, CVS could see premium revenue growth stall, potentially reducing its 2027 net payments by tens of millions of dollars compared with earlier forecasts. Investors reacted sharply to the news, driving CVS shares down alongside peers UnitedHealth Group and Humana as the sector braced for tighter government reimbursements.

Analysts warn that flat rate increases will compress CVS’s medical loss ratio, which stood at 83% in Q4 2025, and strain margins across its integrated pharmacy and insurance operations. CVS management has indicated plans to offset lower Medicare Advantage payments through cost controls in pharmacy benefit management and retail initiatives, including expanding its Prescription Savings Pass program and leveraging its in-house mail-order fulfillment capacity. However, investors remain cautious: Moody’s estimates that each one-percentage-point drop in Medicare Advantage payment growth could reduce CVS’s annual operating profit by approximately $150 million.